US Stock MarketDetailed Quotes
EYEN Eyenovia
- 0.099
- +0.006+6.57%
Close Nov 29 13:00 ET
- 0.094
- -0.005-4.75%
Post 17:01 ET
9.45MMarket Cap-143P/E (TTM)
0.099High0.092Low5.66MVolume0.095Open0.093Pre Close546.15KTurnover7.52%Turnover RatioLossP/E (Static)95.44MShares2.57052wk High2.54P/B7.45MFloat Cap0.07952wk Low--Dividend TTM75.25MShs Float10.740Historical High--Div YieldTTM7.54%Amplitude0.079Historical Low0.096Avg Price1Lot Size
About Eyenovia Company
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Company Profile
SymbolEYEN
Company NameEyenovia
Listing DateJan 25, 2018
Issue Price10.00
Founded2014
CEOMr. Michael M. Rowe
MarketNASDAQ
Employees57
Fiscal Year Ends12-31
Address295 Madison Avenue,Suite 2400
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10017
Phone1-833-393-6684
Websitehttp://www.eyenovia.com
Company Executives
- Name
- Position
- Salary
- Michael M. Rowe
- Chief Financial Officer, Treasurer, Secretary, Chief Executive Officer and Director
- 775.47K
- Bren Kern
- Chief Operating Officer
- 566.99K
- Dr. Tsontcho Ianchulev, M.D.
- Executive Chairman of the Board
- 247.50K
- Michael S. Geltzeiler
- Independent Director
- 57.83K
- Charles E. Mather, IV
- Independent Director
- 148.75K
- Rachel Jacobson
- Independent Director
- 145.00K
- Dr. Ram Palanki
- Independent Director
- 140.00K
- Ellen R. Strahlman, M.D.
- Independent Director
- 162.50K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data